<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The authors investigated the incidence and relative risk of secondary malignant <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in long-term survivors of <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A comprehensive list of 509 patients with primary <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> treated at our institution between February 1973 and March 2000 was identified </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> study patients received chemotherapy and/or surgery on one of six different protocols (T4, 5, 7, 10, 12, and CCG-7921/POG-9351) </plain></SENT>
<SENT sid="3" pm="."><plain>Chemotherapy was scheduled for up to 40 weeks with some variations in the actual treatment period and consisted of various combinations of the following agents: high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="3139">bleomycin</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, dactinomycin, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="2" ids="27899">cisplatin</z:chebi>, and ifosfamide </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Secondary malignant <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (SMN) occurred in 14 of 509 patients </plain></SENT>
<SENT sid="5" pm="."><plain>Only one had <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">pulmonary metastasis</z:e> at diagnosis and subsequent multiple recurrences that required thoracotomies and further modification of the chemotherapy regimen </plain></SENT>
<SENT sid="6" pm="."><plain>The median age at diagnosis for <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> was 16.6 years (range, 3.1-74.4 years) </plain></SENT>
<SENT sid="7" pm="."><plain>The median follow-up was 5.2 years (range, 0.1-25.0 years) </plain></SENT>
<SENT sid="8" pm="."><plain>The time interval from diagnosis of the primary <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> to the development of SMN was 1.3-13.1 years (median, 5.5; 95% confidence interval [CI], 3.6-9.6) </plain></SENT>
<SENT sid="9" pm="."><plain>The most common SMN occurred in the central <z:mp ids='MP_0008912'>nervous</z:mp> system (n = 4): anaplastic <z:hpo ids='HP_0009733'>glioma</z:hpo>, <z:hpo ids='HP_0002858'>meningioma</z:hpo>, high-grade <z:hpo ids='HP_0009733'>glioma</z:hpo>, and maxillary <z:hpo ids='HP_0009592'>astrocytoma</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>There were two cases of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> and one case each of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, high-grade pleomorphic <z:hpo ids='HP_0100242'>sarcoma</z:hpo>, <z:hpo ids='HP_0100243'>leiomyosarcoma</z:hpo>, <z:hpo ids='HP_0100244'>fibrosarcoma</z:hpo>, <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo>, and mucoepidermoid <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>The overall 5 and 10-year cumulative incidences of SMNs were 1.4% +/- 1.1% and 3.1% +/- 1.8% </plain></SENT>
<SENT sid="12" pm="."><plain>The standardized incidence ratio was 4.6 (95% CI, 2.53-7.78, P = 0.00001) for the cohort and 3.64 (95% CI, 1.82-6.52, P = 0.0007) when patients with a history of <z:hpo ids='HP_0009919'>retinoblastoma</z:hpo> or <z:e sem="disease" ids="C0032339" disease_type="Disease or Syndrome" abbrv="">Rothmund-Thomson syndrome</z:e> were excluded </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: The overall incidence of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> in long-term survivors of <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> was significantly higher than the expected incidence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in the general population </plain></SENT>
<SENT sid="14" pm="."><plain>However, the standardized incidence ratios were much lower than those reported for <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin disease</z:e> and <z:hpo ids='HP_0009919'>retinoblastoma</z:hpo> </plain></SENT>
<SENT sid="15" pm="."><plain>Although additional follow-up is warranted, the successes of current treatment regimens consisting of intensive, high-dose chemotherapy in combination with <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> outweigh the risks </plain></SENT>
</text></document>